HeartSciences vs Sangrix
HSCS and SGRX side by side, both in finance services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HSCS and SGRX compare
Sangrix scores higher on the StockData Score (5 against 3 for HeartSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HSCS | SGRX |
|---|---|---|
| Size and price | ||
| Market cap | $9.9M | – |
| Share price | $2.06 | $2.56 |
| Change, 1 year | −32.9% | −99.6% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | −1.54 | 1.40 |
| Employees | – | 1 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2188× | – |
| Profitability | ||
| Gross margin | 60.9% | – |
| Operating margin | −209733% | – |
| Net margin | −227024% | – |
| Return on equity | −1852% | – |
| Return on invested capital | – | −286% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −11.8× | – |
| Current ratio | 0.14 | 6.98 (better) |
| Altman Z-score | −42.02 | – |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 12.8% | – |
| Held by insiders | 19.2% | – |
Go deeper
- HSCS stock overview
- HSCS income statement
- HSCS valuation and score
- SGRX stock overview
- SGRX income statement
- SGRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.